Back to Journals » OncoTargets and Therapy » Volume 6
Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer
Received 2 July 2013
Accepted for publication 29 July 2013
Published 26 August 2013 Volume 2013:6 Pages 1161—1166
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Jae-il Roh, Young Hoon Sung, Han-Woong Lee
Mouse Molecular Genetics Laboratory, Department of Biochemistry, Yonsei Laboratory Animal Research Center, Yonsei University, Seoul, Korea
Abstract: Telomerase is responsible for maintaining the length of telomeres at the ends of chromosomes. Although most somatic cells do not exhibit telomerase activity, it is reactivated in approximately 85% of cancers. This simple and attractive phenomenon steers the development of anticancer drugs targeting telomeres and telomerase. Recent studies have been revealing extratelomeric roles of telomerase in normal tissues, affecting processes that are critical for survival and aging of organisms. In this review, we will discuss the current therapeutic strategies targeting telomeres and telomerase and evaluate their potential advantages and risks with respect to nontelomeric functions.
Keywords: telomerase, telomere, TERT, TERC, telomerase inhibitors
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.